



Solutia Inc.
575 Maryville Centre Drive
P.O. Box 66760

St. Louis, MO 63166-6760
Tel 314-674-1000
Fax 314-674-1585

Dear Distributer,

I am writing to inform you that Flexsys has reached the decision to exit the Primary Accelerators business.

The Flexsys Primary Accelerators product range consists of Benzothiazole, Sodium MBT -50%, Perkacit MBTS, Santocure CBS, Santocure MBS, Santocure TBBS, and Santocure DCBS, which are manufactured at its facility in Antwerp, Belgium, and also include Perkacit MBT and Perkacit ZMBT, which are manufactured at third party facilities on Flexsys' behalf.

Flexsys anticipates that production of the products produced in Antwerp will permanently stop sometime in the second half of 2010. Flexsys will continue to supply these products (Benzothiazole, Sodium MBT -50%, Perkacit MBTS, Santocure CBS, Santocure MBS, Santocure TBBS, and Santocure DCBS) during the remaining production period primarily on a firm order basis, and thereafter on a first-come, first-served basis in order to allow our customers to transition to alternative suppliers. Flexsys will honor all existing contractual commitments that require longer supply of these products.

Perkacit MBT and Perkacit ZMBT will also be available on a firm order basis for a number of months and thereafter on a first-come, first-served basis.

Santocure TBSI is unaffected by this decision and remains available as usual.

This decision does not otherwise affect our distribution agreement. Flexsys will continue to supply product (other than Primary Accelerators) to you under that agreement in accordance with its terms.

Intensifying competition from low cost Asian producers in a structurally oversupplied market has lead to increasing pressure on prices and margins. In spite of our efforts to reduce costs significantly and to find a long-term viable business solution, the business continued to be in an unsustainable financial position.

This decision does not affect the Santoflex PPD manufacturing operations at Antwerp, or any other product line of Flexsys or its parent company Solutia.

This action regarding Primary Accelerators is a necessary and strategic step in positioning Solutia's Flexsys portfolio to remain the global leader in the manufacture and supply of high-quality rubber chemicals that have a competitive advantage in the market.

Enclosed for your reference is the letter we will send to customers. This is to prepare you in the event you are contacted by customers when they receive it.

If you have any questions regarding this communication please do not hesitate to contact your local Flexsys sales manager.

Sincerely,
Richard N, Altice
Vice President, Commercial Services